The CRUK Oxford Centre - Oxford Cancer Symposium is the crowning event in the Oxford Cancer calendar. With approximately 300 people attending in person each year, it provides an opportunity for our members to network and build new collaborations.
Dr Elizabeth Smyth has been elected as Director of Education for the European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncologists in Europe.
Oxford-led study uncovers previously unknown function of platelets as DNA \u2018vacuum cleaners\u2019 in the blood, with profound implications for cancer diagnosis and prenatal screening.
Researchers have developed the first mathematically supported cellular map of lung tissue in idiopathic pulmonary fibrosis (IPF) and uncovered key immune cell interactions that could explain why lungs fail to repair in this deadly disease with no known cure.
Researchers at the University of Oxford and Nanyang Technological University, Singapore have uncovered the mechanism by which cells identify and repair a highly toxic form of DNA damage that causes cancer, neurodegeneration, and premature ageing.
Associate Professor Simon Lord, Director of the Early Phase Clinical Trials Unit within the Department of Oncology and Consultant Medical Oncologist at Oxford University Hospitals NHS Foundation Trust, has been awarded funding from the NIHR to launch a clinical study investigating the impact of insulin resistance on response to endocrine therapy in patients with oestrogen receptor (ER)-positive breast cancer.
The SCAN pathway offers a unique opportunity to access one of the UK\u2019s most comprehensive research infrastructures for non-specific cancer symptoms.
Congratulations to Yuhan Zheng (Papiez group, Big Data Institute), who won first prize for their poster ' Advancing Esophageal Cancer Management with Machine Learning: Multicentre Survival Prediction Models and Novel Insights\u2019, presented at this year's CRUK Oxford Centre Student Symposium.
Members of the Oxford Cancer LynchVax group - Aleksandra Dzhoneva and Luciana Gneo - will be running Cancer Research UK's Race for Life this summer to raise money for life-saving cancer research.
In a collaborative new study, researchers at Ludwig Cancer Research Oxford have identified a potential new therapeutic target in blast phase myeloproliferative neoplasm, a particularly aggressive and hard-to-treat form of leukaemia.
Backed by \u00a35.5m of funding from CRUK and its partners, the hugely ambitious CRC-STARS programme - which is co-lead by Professor Simon Leedham in the Nuffeild Department of Medicine - aims to revolutionise how bowel cancer is treated.
Dr Lennard Lee, a leading cancer vaccine researcher from the Nuffield Department of Medicine, has been recognised at one of the UK\u2019s most esteemed national oncology gatherings.
On 13th June 2025 we welcomed 180 members of the Oxford Cancer Immuno-Oncology Network to the Mathematical Institute in Oxford for our annual in-person Symposium.
Congratulations to Adam Creamer, Pengfei Li, Francisco Lopez-Cuevas, Yuqi Shen and their collaborators who have been awarded funding in the sixth round of the OxCODE Funding Scheme.
Professor Tim Elliott, Co- Director of Oxford Cancer, launched the Oxford Cancer Immuno-Oncology Network (OCION) at the inaugural OCION Symposium in June 2023 [pictured]. With our third annual symposium due to take place this month, we look back at some of OCION\u2019s key achievements.
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
![\"\"](\"https://www.cancer.ox.ac.uk/news/ai-supercomputer-to-help-cancer-vaccine-research/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n